pumabiotechnology.comPuma Biotechnology
pumabiotechnology.com Profile
pumabiotechnology.com
Sub Domains:investor.pumabiotechnology.com
Title:Puma Biotechnology
Description：Puma Biotechnology, Inc is a development stage biopharmaceutical company dedicated to in-licensing and developing novel therapeutics for the treatment of cancer. Puma Biotechnology was founded by Alan H. Auerbach, who previously served as Founder, Chief Executive Officer and President of Cougar Biotechnology, Inc, a company dedicated to in-licensing and developing drugs for the treatment of cancer. Cougar was acquired by Johnson & Johnson in July 2009 for approximately $1 billion.
Keywords：biotechnology, nerlynx, neratinib, neratinib tablets, breast cancer, metastatic, drug development, pb2072, pb272, clinical trials, oncology, her2+, early stage, biopharmaceutical, in-licensing, cancer treatment, oncology, extended adjuvant therapy...
Discover pumabiotechnology.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
pumabiotechnology.com Information
| Website / Domain: | pumabiotechnology.com |
| HomePage size: | 29.671 KB |
| Page Load Time: | 0.282827 Seconds |
| Website IP Address: | 148.72.1.102 |
| Isp Server: | Spacenet Inc. |
pumabiotechnology.com Ip Information
| Ip Country: | United States |
| City Name: | McLean |
| Latitude: | 38.952758789062 |
| Longitude: | -77.235061645508 |
pumabiotechnology.com Keywords accounting
| Keyword | Count |
|---|---|
| biotechnology | 3 |
| nerlynx | 8 |
| neratinib | 13 |
| neratinib tablets | 0 |
| breast cancer | 15 |
| metastatic | 5 |
| drug development | 0 |
| pb2072 | 0 |
| pb272 | 0 |
| clinical trials | 0 |
| oncology | 2 |
| her2+ | 0 |
| early stage | 7 |
| biopharmaceutical | 0 |
| in-licensing | 0 |
| cancer treatment | 0 |
| extended adjuvant therapy | 0 |
pumabiotechnology.com Httpheader
| Date: Sat, 01 Aug 2020 19:05:18 GMT |
| Server: Apache |
| Upgrade: h2,h2c |
| Connection: Upgrade, Keep-Alive |
| Last-Modified: Wed, 29 Jul 2020 22:08:41 GMT |
| ETag: "1e219c-667c-5ab9bcc72ae30-gzip" |
| Accept-Ranges: bytes |
| Cache-Control: max-age=2592000 |
| Expires: Mon, 31 Aug 2020 19:05:18 GMT |
| Vary: Accept-Encoding,User-Agent |
| Content-Encoding: gzip |
| Content-Length: 6012 |
| Keep-Alive: timeout=5 |
| Content-Type: text/html |
pumabiotechnology.com Meta Info
| content="Puma Biotechnology, Inc is a development stage biopharmaceutical company dedicated to in-licensing and developing novel therapeutics for the treatment of cancer. Puma Biotechnology was founded by Alan H. Auerbach, who previously served as Founder, Chief Executive Officer and President of Cougar Biotechnology, Inc, a company dedicated to in-licensing and developing drugs for the treatment of cancer. Cougar was acquired by Johnson & Johnson in July 2009 for approximately $1 billion." name="description"/ |
| content="biotechnology, nerlynx, neratinib, neratinib tablets, breast cancer, metastatic, drug development, pb2072, pb272, clinical trials, oncology, her2+, early stage, biopharmaceutical, in-licensing, cancer treatment, oncology, extended adjuvant therapy" name="keywords"/ |
| content="Puma Biotechnology" name="author"/ |
| content="text/html;charset=utf-8" http-equiv="Content-Type"/ |
148.72.1.102 Domains
| Domain | WebSite Title |
|---|
pumabiotechnology.com Similar Website
| Domain | WebSite Title |
|---|---|
| Puma Biotechnology | |
| Puma Biotechnology, Inc. - Investor Relations | |
| Biotechnology Conferences | Top Biotechnology Conferences | Biotechnology Events | Industrial Biotec | |
| EL PUMA CUSCO 3 ★ | |
| Puma Swede's Blog | |
| PUMA.COM | Forever Faster | |
| PUMA.com | Forever Faster. | |
| Boutique en ligne Puma Global | |
| PUMA Australia Online Store | Forever Faster. | |
| Massachusetts Biotechnology Council | |
| Santa Cruz Biotechnology | |
| National Center for Biotechnology Information | |
| Benefits & Safety of Biotechnology Database | |
| Biotechnology Innovation Organization | BIO | |
| Biotechnology in Agriculture College of Agricultural |
pumabiotechnology.com Traffic Sources Chart
pumabiotechnology.com Alexa Rank History Chart
pumabiotechnology.com Html To Plain Text
July 27, 2020 - Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers Read July 23, 2020 - to Host Conference Call to Discuss Second Quarter Financial Results Read July 16, 2020 - Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer Read May 7, 2020 - Reports First Quarter 2020 Financial Results Read May 7, 2020 - Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer Read May 6, 2020 - to Present at the BofA Securities Health Care Conference 2020 Read April 30, 2020 - and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea Read April 23, 2020 - to Host Conference Call to Discuss First Quarter Financial Results Read March 25, 2020 - Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read February 28, 2020 - to Present at Cowens Annual Health Care Conference Read February 26, 2020 - Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer Read February 20, 2020 - Reports Fourth Quarter and Full Year Financial Results Read February 5, 2020 - to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results Read January 13, 2020 - Releases Slides to be Presented at the J.P. Morgan Healthcare Conference Read January 7, 2020 - to Present at the J.P. Morgan Healthcare Conference Read December 13, 2019 - Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS Read December 12, 2019 - plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer Read December 11, 2019 - Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium Read December 2, 2019 - Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer Read December 2, 2019 - Amends License Agreement with Pierre Fabre to Include Additional Countries Read November 6, 2019 - Reports Third Quarter 2019 Financial Results Read November 5, 2019 - Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer Read November 4, 2019 - to Present at the Credit Suisse Healthcare Conference Read October 23, 2019 - to Host Conference Call to Discuss Third Quarter Financial Results Read October 2, 2019 - FDA Approves Labeling Supplement for s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Read September 25, 2019 - to Present at Cantor Global Healthcare Conference Read September 11, 2019 - Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer Read September 4, 2019 - Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer Read September 3, 2019 - FDA Grants Orphan Drug Designation to s NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases Read September 3, 2019 - to Present at the H.C. Wainwright 21st Annual Global Investment Conference Read Upcoming Events Aug. 6, 2020 - 2Q-2020 Financial Results Conference Call More Past Events May 13, 2020 - BofA Securities Health Care Conference 2020 More May 7, 2020 - 1Q-2020 Financial Results Conference Call More March 4, 2020 - Cowen and Company 40th Annual Health Care Conference More Feb. 20, 2020 - 4Q-2019 Financial Results Conference Call More Jan. 15, 2020 - 38th Annual J.P. Morgan Healthcare Conference More Dec. 10, 2019 - San Antonio Breast Cancer Symposium More Nov. 12, 2019 - Credit Suisse 28th Annual Healthcare Conference More Nov. 6, 2019 - 3Q-2019 Financial Results Conference Call More October 3, 2019 - Cantor Global Healthcare Conference More September 10, 2019 - H.C. Wainwright 21st Annual Global Investment Conference More September 5, 2019 - Citis 14th Annual Biotech Conference More August 8, 2019 - 2Q-2019 Financial Results Conference Call More July 3-6, 2019 - ESMO 2019 Annual Meeting More May 31, 2019 - ASCO 2019 Annual Meeting More May 29, 2019 - Jefferies 2019 Global Healthcare Conference More May 15, 2019 - Bank of America Merrill Lynch 2019 Health Care Conference More May 9, 2019 - 1Q-2019 Financial Results Conference Call More March 29 April 3, 2019 - AACR Annual Meeting 2019 More March 16-19, 2019 - Society of Gynecologic Oncology (SGO) 2019 Annual Meeting More March 12, 2019 - Cowen and Company 39th Annual Health Care Conference More February 28, 2019 - 4Q-2018 Financial Results Conference Call More February 14, 2019 - Guggenheim Healthcare Talks Idea Forum, Oncology Day More January 9, 2019 - JP Morgan 37th Annual Healthcare Conference More December 17, 2018 - NALA Trial Update Call More November 14, 2018 - Credit Suisse 27th Annual Healthcare Conference More November 1, 2018 - 3Q-2018 Financial Results Conference Call More October 1, 2018 - Cantor Global Healthcare Conference More September 12, 2018 - Morgan Stanley 16th Annual Global Healthcare Conference More September 6, 2018 - Citis 13th Annual Biotech Conference More August 9, 2018 - 2Q-2018 Financial Results Conference Call More June 7, 2018 - Jefferies Global Healthcare Conference More June 1-5, 2018 - ASCO 2018 Annual Meeting More May 16, 2018 - Bank of America Merrill Lynch Health Care Conference 2018 More May 9, 2018 - 1Q-2018 Financial Results Conference Call More March 13, 2018 - Cowen and Company 38th Annual Health Care Conference More March 1, 2018 - 4Q-2017 Financial Results Conference Call More February 14, 2018 - LEERINK Partners 7th Annual Global Healthcare Conference More December 5 9, 2017 - San Antonio Breast Cancer Symposium More November 15, 2017 - Stifel 2017 Healthcare Conference More November 9, 2017 - 3Q-2017 Financial Results More November 7, 2017 - Credit Suisse Healthcare Conference More Annual Report Archives , Inc. 10880 Wilshire Blvd., Suite 2150 Los Angeles, CA 90024 424-248-6500 Main 424-248-6501 Fax Medical Inquiries: 1-844-MED-PUMA (1-844-633-7862), or medinfo@pumabiotechnology.com Business Development: info@pumabiotechnology.com Investor Relations: ir@pumabiotechnology.com Follow Us: © 2020 , Inc. | Privacy Policy | Legal Notice | Site Map...
pumabiotechnology.com Whois
"domain_name": [
"PUMABIOTECHNOLOGY.COM",
"pumabiotechnology.com"
],
"registrar": "GoDaddy.com, LLC",
"whois_server": "whois.godaddy.com",
"referral_url": null,
"updated_date": [
"2020-01-04 21:53:55",
"2020-01-04 21:53:45"
],
"creation_date": "2010-08-26 19:52:17",
"expiration_date": "2020-08-26 19:52:17",
"name_servers": [
"NS67.DOMAINCONTROL.COM",
"NS68.DOMAINCONTROL.COM"
],
"status": [
"clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited",
"clientRenewProhibited https://icann.org/epp#clientRenewProhibited",
"clientTransferProhibited https://icann.org/epp#clientTransferProhibited",
"clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited",
"clientTransferProhibited http://www.icann.org/epp#clientTransferProhibited",
"clientUpdateProhibited http://www.icann.org/epp#clientUpdateProhibited",
"clientRenewProhibited http://www.icann.org/epp#clientRenewProhibited",
"clientDeleteProhibited http://www.icann.org/epp#clientDeleteProhibited"
],
"emails": [
"abuse@godaddy.com",
"pumabiotechnology.com@domainsbyproxy.com"
],
"dnssec": "unsigned",
"name": "Registration Private",
"org": "Domains By Proxy, LLC",
"address": [
"DomainsByProxy.com",
"14455 N. Hayden Road"
],
"city": "Scottsdale",
"state": "Arizona",
"zipcode": "85260",
"country": "US"